Missing the mark in FGFR1-amplified squamous cell cancer of the lung

Paul K Paik^{1

2}, Charles M Rudin^{3

4}

Affiliations

¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. paikp@mskcc.org.
² Weill Cornell Medical College, New York, New York. paikp@mskcc.org.
³ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Weill Cornell Medical College, New York, New York.

Free article

Editorial

Paul K Paik et al. Cancer. 2016 Oct.

Free article

. 2016 Oct;122(19):2938-40.

doi: 10.1002/cncr.30131. Epub 2016 Jun 17.

Paul K Paik^{1

2}, Charles M Rudin^{3

4}

¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. paikp@mskcc.org.
² Weill Cornell Medical College, New York, New York. paikp@mskcc.org.
³ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Weill Cornell Medical College, New York, New York.

No abstract available

Comment on

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase 2 study.
Lim SH, Sun JM, Choi YL, Kim HR, Ahn S, Lee JY, Lee SH, Ahn JS, Park K, Kim JH, Cho BC, Ahn MJ. Lim SH, et al. Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17. Cancer. 2016. PMID: 27315356 Clinical Trial.